



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IFee

1648

Patent Application of

Michael S. Roberts, et al

Atty. Ref.: 2370-84

Serial No. 10/044,955

TC/A.U.: 1648

Filed: January 15, 2002

Examiner: Timothy M. Brown

For: TREATMENT OF NEOPLASMS WITH VIRUSES

\* \* \* \* \*

August 9, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT


In response to the second complete paragraph on page 2 of the Action mailed March 9, 2004, attached are further copies of the references which were redacted by the Examiner from the PTO 1449 forms attached to the Action (please note that the reference marked by a double (\*\*) asterisk will be provided to the Examiner in a Supplemental Information Disclosure upon receipt by the undersigned). Copies of the listed references have already been submitted by applicants and it is believed, therefore, that no IDS fee is required for the present re-submission of copies of the documents. However, should it be determined otherwise (it is believed that should not be the case), the Commissioner is authorized to charge our deposit account No. 14-1140 for the requisite IDS fee.

This is not to be construed as a representation that a search has been made or that no better prior art exists, or that a reference is relevant merely because cited.

The Examiner is requested to initial the attached form PTO-1449 and to return a copy of the initialed document to the undersigned as an indication that the attached references have been considered and made of record.

Respectfully submitted,


**NIXON & VANDERHYE P.C.**

By: 

Leonard C. Mitchard  
Reg. No. 29,009

LCM:lfm

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE  
CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al

FILING DATE

TC/A.U.

January 15, 2002

1648

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	FILING DATE		
				CLASS	SUBCLASS	IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES
WO 96/26285 /	08/1996	WIPO			
WO 94/19022 /	09/1994	WIPO			
WO 99/18799 /	04/1999	WIPO			
WO 99/45783 /	09/1999	WIPO			
WO 96/34625 /	11/1996	WIPO			
WO 00/62735 /	10/2000	WIPO			
WO 99/08692 /	02/1999	WIPO			
WO 94/25627 /	11/1994	WIPO			
WO 93/18790 /	09/1993	WIPO			
WO 86/00811 /	02/1986	WIPO			
WO 86/00529 /	01/1986	WIPO			
WO 99/29343 /	06/1999	WIPO			
WO 99/55345 /	11/1999	WIPO			
WO 00/45853 /	08/2000	WIPO			
WO 99/04026 /	01/1999	WIPO			
WO 97/26904 /	07/1997	WIPO			
WO 96/03997 /	02/1996	WIPO			
WO 95/32706 /	12/1995	WIPO			
WO 89/07445 /	08/1989	WIPO			
WO 97/01358 /	01/1997	WIPO			
WO 97/04805 /	02/1997	WIPO			
WO 94/18992 /	09/1994	WIPO			
JP (A) 58-116422 /	07/1983	JP			
0 564 121 A2 /	10/1993	EP			
1,069,144 /	05/1967	GB			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Ahlert, T., et al; "Isolation of a Human Melanoma Adapted Newcastle Disease Virus Mutant with Highly Selective Replication Patterns"; <i>Cancer Research</i> ; Vol. 50, pp. 5962-5968 (1990).
	Andreasky, S.S., et al; "The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors"; <i>Proc. Natl. Acad. Sci.</i> ; Colloquium Paper; Vol. 93, pp. 11313-11318 (1996).
	Arroyo, P.J., et al; "Active Specific Immunotherapy with Vaccinia Colon Oncolysate Enhances the Immunomodulatory and Antitumor Effects of Interleukin-2 and Interferon $\alpha$ in a Murine Hepatic Metastasis Model"; <i>Cancer Immunol Immunother</i> ; Vol. 31, pp. 305-311 (1990).
	Asada, T.; "Treatment of Human Cancer with Mumps Virus"; <i>Cancer</i> ; Vol. 34; pp. 1907-1928 (1974).
	Balachandran, S., et al; "Activation of the dsRNA-Dependent Protein Kinase, PKR, Induces Apoptosis Through FADD-Mediated Death Signaling"; <i>The EMBO Journal</i> ; Vol. 17, No. 23, pp. 6888-6902 (1998).
	Balachandran, S., et al; "Vesicular Stomatitis Virus (VSV) Therapy of Tumors"; <i>Life</i> ; Vol. 50, pp. 135-138 (2000).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.



(Use several sheets if necessary)


INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO.	SERIAL NO.
	2370-84	10/044,955
	APPLICANT	
	Michael S. Roberts, et al	
	FILING DATE	TC/A.U.
	January 15, 2002	1648

	Barber, G.N., et al; "The 58-kilodalton Inhibitor of the Interferon-Induced Double-Stranded RNA-Activated Protein Kinase is a Tetratricopeptide Repeat Protein with Oncogenic Properties"; <i>Proc. Natl. Acad. Sci.</i> ; Vol. 91, pp. 4278-4282 (1994).
	Bart, R.S., et al; "Role of Interferon in the Anti-Melanoma Effects of Poly (I).Poly (C) and Newcastle Disease Virus"; <i>Nature New Biology</i> ; Vol. 245; pp. 229-230 (1973).
	Beattie, E., et al; "Host-Range Restriction of Vaccinia Virus E3L-Specific Deletion Mutants"; <i>Virus Genes</i> ; Vol. 12, No. 1, pp. 89-94 (1996).
	Beverley, P.C.L., et al; "Immune Responses in Mice to Tumour Challenge After Immunization with Newcastle Disease Virus-Infected or X-Irradiated Tumor Cells or Cell Fractions"; <i>Int. J. Cancer</i> ; Vol. 11, pp. 212-223 (1973).
	Bischoff, J.R., et al; "An Adenovirus Mutant That Replicates Selectively in p53-Deficient Human Tumor Cells"; <i>Science</i> ; Vol. 274; pp. 373-376 (1996).
	Blaese, R.M., et al; "In situ Delivery of Suicide Genes for Cancer Treatment"; <i>European Journal of Cancer</i> ; Vol. 30A, No. 8; pp. 1193-1201 (1994).
	Bluming, A.Z., et al; "Regression of Burkitt's Lymphoma in Association with Measles Infection"; <i>The Lancet</i> ; pp. 105-106 (1971).
	Bohle, W., et al; "Postoperative Active Specific Immunization in Colorectal Cancer Patients with Virus-Modified Autologous Tumor-Cell Vaccine"; <i>Cancer</i> ; Vol. 66, NO. 7, pp. 1517-1523 (1990).
	Buller, R.M.L., et al; "Cell Proliferative Response to Vaccinia Virus is Mediated by VGF"; <i>Virology</i> , Vol. 164; pp. 182-192 (1988).
	Buller, R.M.L., et al; "Decreased Virulence of Recombinant Vaccinia Virus Expression Vectors is Associated with a Thymidine Kinase-Negative Phenotype"; <i>Nature</i> , Vol. 317, pp. 813-815 (1985).
	Cassel, W.A., et al; "Newcastle Disease Virus as an Antineoplastic Agent"; <i>Cancer</i> ; Vol. 18; pp. 863-868 (1965).
	Cassel, W.A., et al; "A Phase II Study on the Postsurgical Management of Stage II Malignant Melanoma with a Newcastle Disease Virus Oncolysate"; <i>Cancer</i> ; Vol. 52, pp. 856-860 (1983).
	Cassel, W.A., et al; "A Ten-Year Follow-up on Stage II Malignant Melanoma Patients Treated Postsurgically with Newcastle Disease Virus Oncolysate"; <i>Med. Oncol. &amp; Tumor Pharmacother.</i> ; Vol. 9, No. 4, pp. 169-171 (1992).
	Chambers, R., et al; "Comparison of Genetically Engineered Herpes Simplex Viruses for the Treatment of Brain Tumors in a scid Mouse Model of Human Malignant Glioma"; <i>Proc. Natl. Acad. Sci.</i> ; Vol. 92; pp. 1411-1415 (1995).
	Child, S.J., et al; "Insertional Inactivation of the Large Subunit of Ribonucleotide Reductase Encoded by Vaccinia Virus is Associated with Reduced Virulence in Vivo"; <i>Virology</i> ; Vol. 174, pp. 625-629 (1990).
	Chou, J., et al; "Association of a M <sub>r</sub> 90,000 Phosphoprotein with Protein Kinase PKR in Cells Exhibiting Enhanced Phosphorylation of Translation Initiation Factor eIF-2 $\alpha$ and Premature Shutoff of Protein Synthesis after Infection with $\lambda$ 34.5' Mutants of Herpes Simplex Virus 1"; <i>Proc. Natl. Acad. Sci.</i> ; Vol. 92, pp. 10516-10520 (1995).
	Clark, H.F., et al; "Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season"; <i>The Journal of Infectious Diseases</i> ; Vol. 158, No. 3; pp. 570-587 (1988).
	Cotran, R.S., et al; "Kinetics of Tumor Cell Growth"; <i>Robbins Pathologic Basis of Disease</i> , 4 <sup>th</sup> Edition; pp. 251-253 (1989).
	Csatary, L.K., et al; "Attenuated Veterinary Virus Vaccine for the Treatment of Cancer"; <i>Cancer Detection and Prevention</i> ; Vol. 17, No. 6; pp. 617-627 (1993).
	Csatary, L.K.; "Viruses in the Treatment of Cancer"; <i>The Lancet</i> ; pp. 825-826 (1971).
	Csatary, L.K. et al; "Virus Vaccines for the Treatment of Cancer"; <i>Orvosi Hetilap</i> ; Vol. 131; pp. 2585-2588 (1990).
	Durbin, J.E., et al; "Targeted Disruption of the Mouse <i>Stat1</i> Gene Results in Compromised Innate Immunity to Viral Disease"; <i>Cell</i> ; Vol. 84, pp. 443-450 (1996).
	Eaton, M.D., et al; "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma"; <i>Journal of the National Cancer Institute</i> ; Vol. 39, No. 6, pp. 1089-1097 (1967).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE  
CITATION


ATTY. DOCKET NO. 2370-84 SERIAL NO. 10/044,955  
 CITATION APPLICANT Michael S. Roberts, et al  
 FILING DATE January 15, 2002 TC/A.U. 1648  
 (Use several sheets if necessary)

	Eaton, M.D., et al; "Autoimmunity Induced by Injection of Virus-Modified Cell Membrane Antigens in Syngeneic Mice"; Vol. 15, No. 1; pp. 322-329 (1977).
	Eck, S.L., et al; "Gene-Based Therapy", <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i> ; 9 <sup>th</sup> Edition, Chapter 5. pp. 77-101.
	Faaberg, K.S., et al; "Strain Variation and Nuclear Association of Newcastle Disease Virus Matrix Protein"; <i>Journal of Virology</i> ; Vol. 62, No. 2; pp. 586-593 (1988).
	Field, H.J., et al; "The Pathogenicity of Thymidine Kinase-Deficient Mutants of Herpes Simplex Virus in Mice"; <i>J. Hyg. Camb.</i> ; Vol. 81, pp. 267-277; (1978).
	Foy, T.M., et al; "In Vivo CD40-gp39 Interactions are Essential for Thymus-Dependent Humoral Immunity. II. Prolonged Suppression of the Humoral Immune Response by an Antibody to the Ligand for CD40, gp39"; <i>J. Exp. Med.</i> ; Vol. 178, pp. 1567-1575 (1993).
	Franceur, A. M. et al; "The Isolation of Interferon-Inducing Mutants of Vesicular Stomatitis Virus with Altered Viral P Function for the Inhibition of Total Protein Synthesis"; <i>Virology</i> ; Vol. 160, pp. 236-245 (1987).
*	Ganly, et al; "Phase I Trial of Intratumoral Injection with an E1B-Attenuated Adenovirus, ONYX-015, in Patients with Recurrent p53(-) Head and Neck Cancer"; <i>Proceedings of ASCO</i> ; Vol. 16; p. 382a; Abstract 1362 (1997).
*	Gastl, G., et al; "Retroviral Vector-Mediated Lymphokine Gene Transfer into Human Renal Cancer Cells"; <i>Cancer Research</i> ; Vol. 52, pp. 6229-6236 (1992).
	Goldstein, D.J., et al; "Factor(s) Present in Herpes Simplex Virus Type 1-Infected Cells Can Compensate for the Loss of the Large Subunit of the Viral Ribonucleotide Reductase: Characterization of an ICP6 Deletion Mutant"; <i>Virology</i> ; Vol. 166; pp.41-51 (1988).
	Gresser, I.; "Exogenous Interferon and Inducers of Interferon in the Treatment of Balb/c Mice Inoculated with RC <sub>19</sub> Tumour Cells"; <i>Nature</i> ; Vol. 223; pp 844-845 (1969).
*	Gresser, I.; "Inhibitory Effect of Interferon on Murine Sarcoma and Leukaemia Virus Infection in Vitro"; <i>Nature</i> ; Vol. 223; p 845 (1969).
	Gross, S.; "Measles and Leukemia"; <i>The Lancet</i> ; pp. 397-398 (1971).
	Haines, G.K., et al; "Correlation of the Expression of Double-Stranded RNA-Dependent Protein Kinase (p68) with Differentiation in Head and Neck Squamous Cell Carcinoma"; <i>Virchows Archiv. B Cell Pathol.</i> ; Vol. 63; pp. 289-295 (1993).
	Hanson, R.P., et al; "Identification of Vaccine Strains of Newcastle Disease Virus"; <i>Science</i> ; Vol. 122, pp. 156-157 (1955).
	Hashiro, G., et al; "The Preferential Cytotoxicity of Reovirus for Certain Transformed Cell Lines" <i>Archives of Virology</i> ; Vol. 54, pp. 307-315 (1977).
	Heise, C., et al; "ONYX-015, an E1B Gene-Attenuated Adenovirus, Causes Tumor-Specific Cytolysis and Antitumoral Efficacy that can be Augmented by Standard Chemotherapeutic Agents"; <i>Nature Medicine</i> ; Vol. 3 No. 6, pp. 639-645 (1997).
	Holzaepfel, J.H., et al; "The Use of APC <sub>3</sub> Virus as a Cancericidal Agent"; <i>Cancer</i> ; Vol. 10, pp. 577-580 (1957).
	Horvath, J., et al; "Comparison of Oncolytic Newcastle Disease Virus Strains"; <i>Experimental Therapeutics</i> ; #2619; (Cancer Institute, St. Joseph's Hospital, Tampa, FL).
	Howard, B., et al; "Retrovirus-Mediated Gene Transfer of the Human $\gamma$ -IFN Gene: A Therapy for Cancer"; <i>Annals New York Academy of Sciences</i> ; pp. 167-187.
	Hughes, S.J., et al; "Vaccinia Virus Encodes an Active Thymidylate Kinase That Complements a cdc8 Mutant of <i>Saccharomyces cerevisiae</i> *"; <i>The Journal of Biological Chemistry</i> ; Vol. 266, No. 30; pp. 20103-20109 (1991).
	Ideo, G., et al; "Viruses in the Treatment of Cancer"; <i>The Lancet</i> ; pp. 825-826 (1971).
	Ikeda, H., et al; "Detection of Heterozygous Mutation in the Retinoblastoma Gene in a Human Pituitary Adenoma Using PCR-SSCP Analysis and Direct Sequencing"; <i>Endocrine Pathology</i> ; Vol. 6, No. 3; pp. 189-196 (1995).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.	SERIAL NO.
2370-84	10/044,955
APPLICANT	
Michael S. Roberts, et al	
FILING DATE	TC/A.U.
January 15, 2002	1648


(Use several sheets if necessary)

	Imani, F., et al; "Inhibitory Activity for the Interferon-Induced Protein Kinase is Associated with the Reovirus Serotype 1 $\sigma$ Protein"; <i>Proc. Natl Acad. Sci.</i> ; Vol. 85, pp. 7887-7891 (1988).
	Izbicka, et al; "Effects of ONYX Adenovirus Preparations on Human Tumor Colony Forming Units"; <i>Proceedings of ASCO</i> ; Vol. 16; p. 433a; Abstract 1554 (1997).
	James, C.D., et al; "Chromosome 9 Deletion Mapping Reveals Interferon $\alpha$ and Interferon $\beta$ -1 Gene Deletions in Human Glial Tumors"; <i>Cancer Research</i> ; Vol. 51, pp. 1684-1688 (1991).
	Joklik, W.K.; "Interferons"; <i>Virology</i> ; pp. 383-410 (1990).
	Kalvakolanu, D.V.R., et al; "Differentiation-Dependent Activation of Interferon-Stimulated Gene Factors and Transcription Factor NF- $\kappa$ B in Mouse Embryonal Carcinoma Cells"; <i>Proc. Natl. Adac. Sci.</i> ; Vol. 90, pp. 3167-3171 (1993).
	Katze, M.G.; "Regulation of the Interferon-Induced PKR: Can Viruses Cope?"; <i>Trends in Microbiology</i> ; Vol. 3, No. 2; pp. 75-78 (1995).
	Kenney, S., et al; "Viruses as Oncolytic Agents: a New Age for "Therapeutic" Viruses?"; <i>Journal of the National Cancer Institute</i> ; Vol. 86, No. 16, Editorial Issue; pp. 1185-1186 (1994).
	Kerr, S.M., et al; "Vaccinia DNA Ligase Complements <i>Saccharomyces cerevisiae cdc9</i> , Localizes in Cytoplasmic Factories and Affects Virulence and Virus Sensitivity to DNA Damaging Agents"; <i>The EMBO Journal</i> ; Vol. 10, No. 13; pp. 4343-4350 (1991).
	Kirchner, H.H., et al; "Adjuvant Treatment of Locally Advanced Renal Cancer with Autologous Virus-Modified Tumor Vaccines"; <i>World J Urol</i> ; Vol. 13; pp. 171-173 (1995).
	Kirn, D.H., et al; "Replicating Viruses as Selective Cancer Therapeutics"; <i>Molecular Medicine Today</i> ; PH:S1357-4310(96)10050-2; pp. 519-527 (1996).
	Kirn, et al; "ONYX-015, A Selectively Replicating Adenovirus, Has Antitumoral Activity Following IV Administration Alone and in Combination with Chemotherapy"; <i>Proceedings of ASCO</i> ; Vol. 16, p. 437a; Abstract 1564 (1997).
	Kirn, et al; "ONYX-015 Selectively Replicates in and Lyses Cells Lacking Functional Small p53"; <i>Proceedings for the American Association for Cancer Research</i> ; Vol. 37; p. 352; Abstract 2400 (1996).
	Korth, M.J., et al; "Cloning, Expression, and Cellular Localization of the Oncogenic 58-kDa Inhibitor of the RNA-Activated Human and Mouse Protein Kinase"; <i>Gene</i> ; Vol. 170, pp. 181-188 (1996).
	Linge, C., et al; "Interferon System Defects in Human Malignant Melanoma"; <i>Cancer Research</i> ; Vol. 55, pp. 4099-4104 (1995).
	Lorence, R.M., et al; "Complete Regression of Human Fibrosarcoma Xenografts after Local Newcastle Disease Virus Therapy"; <i>Cancer Research</i> ; Vol. 54; pp. 6017-6021 (1994).
	Lorence, R.M., et al; "Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- $\alpha$ and Augmentation of Its Cytotoxicity"; <i>Journal of the National Cancer Institute</i> ; Vol. 80, No. 16, pp. 1305-1313 (1988).
	Lorence, R.M., et al; "Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy"; <i>Journal of the National Cancer Institute</i> ; Vol. 86, No. 16; pp. 1228-1233 (1994).
	Machida, H., et al; "Effect of Nucleosides on Interferon Production and Development of Antiviral State Induced by Poly I Poly C"; <i>Microbiol. Immunol.</i> ; Vol. 23, No. 7; pp. 643-650 (1979).
	Maeda, A., et al; "Isolation and Characterization of Defective Interfering Particle of Newcastle Disease Virus"; <i>Microbiol. Immunol.</i> ; Vol. 22, No. 12, pp. 775-784 (1978).
	Maheshwari, R.K., et al; "Low Infectivity of Vesicular Stomatitis Virus (VSV) Particles Released from Interferon-Treated Cells is Related to Glycoprotein Deficiency"; <i>Biochemical and Biophysical Research Communications</i> ; Vol. 117, No. 1, pp. 161-168; (1983).
	Martuza, R.; "Novel Treatment Approach for Malignant Brain Tumors Developed at Georgetown"; <i>Examiner</i> ; <i>Georgetown University Medical Center</i> ; pp. 1-8 (1995).
	Martuza, R.L., et al; "Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant"; <i>Science</i> ; Vol. 252; pp. 853-856 (1991).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO.	SERIAL NO.	
		2370-84	10/044,955	
		APPLICANT	Michael S. Roberts, et al	
		FILING DATE	TC/A.U.	
		January 15, 2002	1648	
<p><b>Mathews, M.B., et al;</b> "Adenovirus Virus-Associated RNA and Translation Control"; <i>Journal of Virology</i>; Vol. <b>65</b>, No. 11; pp. 5657-5662 (1991).</p> <p><b>Meignier, B., et al;</b> "In Vivo Behavior of Genetically Engineered Herpes Simplex Viruses R7017 and R7020. II. Studies in Immunocompetent and Immunosuppressed Owl Monkeys (<i>Aotus trivirgatus</i>)"; <i>The Journal of Infectious Diseases</i>; Vol. <b>162</b>; pp.313-321 (1990).</p> <p><b>Mineta, T., et al;</b> "Attenuated Multi-Mutated Herpes Simplex Virus-1 for the Treatment of Malignant Gliomas"; <i>Nature Medicine</i>; Vol. <b>1</b>, No. 9; pp. 938-943 (1995).</p> <p><b>Murray, D.R., et al;</b> "Viral Oncolysate in the Management of Malignant Melanoma"; <i>Cancer</i>; Vol. <b>40</b>, No. 2, pp.680-686 (1977).</p> <p><b>Murphy, F.A., et al;</b> "Virus Taxonomy"; <i>Virology</i>; Second Edition; Vol. 1; Chapter 2; pp. 9-35 (1990).</p> <p><b>Nickels, M.S., et al;</b> "Identification of an Amino Acid Change that Affects N Protein Function in Vesicular Stomatitis Virus"; <i>Journal of General Virology</i>; Vol. <b>75</b>, pp. 3591-3595 (1994).</p> <p><b>Pasquinucci, G.;</b> "Possible Effect of Measles on Leukemia"; <i>The Lancet</i>; p 136 (1971).</p> <p><b>Pennisi, E.;</b> "Will a Twist of Viral Fate Lead to a New Cancer Treatment?"; <i>Science</i>; Vol. <b>274</b>, pp. 342-343 (1996).</p> <p><b>Peplinski, G.R., et al;</b> "Prevention of Murine Breast Cancer by Vaccination with Tumor Cells Modified by Cytoline-Producing Recombinant Vaccinia Viruses"; <i>Annals of Surgical Oncology</i>; Vol. <b>3</b>, No. 1; pp. 15-23 (1996)..</p> <p><b>Perkus, M.E., et al;</b> "Deletion of 55 Open Reading Frames from the Termini of Vaccinia Virus"; <i>Virology</i> Vol. <b>180</b>; pp. 406-410 (1991).</p> <p><b>Petricoin III, E., et al;</b> "Human Cancer Cell Lines Express a Negative Transcriptional Regulator of the Interferon Regulatory Factor Family of DNA Binding Proteins"; <i>Molecular and Cellular Biology</i>; Vol. <b>14</b>, No. 2, pp. 1477-1486 (1994).</p> <p><b>Reichard, K.W., et al;</b> "Newcastle Disease Virus Selectively Kills Human Tumor Cells"; <i>Journal of Surgical Research</i>; Vol. <b>52</b>, pp. 448-453 (1992).</p> <p><b>Restifo, N.P., et al;</b> "A Nonimmunogenic Sarcoma Transduced with the cDNA for Interferon <math>\gamma</math> Elicits CD8<math>^{+}</math> T Cells against the Wild-type Tumor: Correlation with Antigen Presentation Capability"; <i>The Journal of Experimental Medicine</i>; Vol. <b>175</b>, pp. 1423-1431 (1992).</p> <p><b>Rodriguez, R., et al;</b> "Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-Specific Antigen-Positive Prostate Cancer Cells"; <i>Cancer Research</i>; Vol. <b>57</b>; pp. 2559-2563 (1997).</p> <p><b>Rosenbergová, M., et al;</b> "Purification of Newcastle Disease Virus by Chromatography on Controlled-Pore Glass Bead Column"; <i>Acta Virol.</i>; Vol <b>25</b>, pp. 31-35 (1981).</p> <p><b>Rukavishnikova, G.E., et al;</b> "Some Immunological Mechanisms of the Influenza Virus Antitumour Effect"; <i>Acta Virol.</i>; Vol. <b>20</b>, pp. 387-394 (1976).</p> <p><b>Schirrmacher, V., et al;</b> "Successful Application of Non-Oncogenic Viruses for Antimetastatic Cancer Immunotherapy"; <i>Institut für Immunologie Und Genetik AM Deutschen Krebsforschungszentrum, 6900 Heidelberg, Germany</i>; pp. 19-49 (1986).</p> <p><b>Schloer, G.M., et al;</b> "Relationship of Plaque Size and Virulence for Chickens of 14 Representative Newcastle Disease Virus Strains"; <i>Journal of Virology</i>; Vol. <b>2</b>, No. 1; pp. 40-47 (1968).</p> <p><b>Schnell, M.J., et al;</b> "Construction of a Novel Virus that Targets HIV-1-Infected Cells and Controls HIV-1 Infection"; <i>Cell</i>; Vol. <b>90</b>; pp. 849-857 (1997).</p> <p><b>Schubert, M., et al;</b> "Primary Structure of the Vesicular Stomatitis Virus Polymerase (L) Gene: Evidence for a High Frequency of Mutations"; <i>Journal of Virology</i>; Vol. <b>51</b>, No. 2, pp. 505-514 (1984).</p> <p><b>Shoham, J., et al;</b> "Augmentation of Tumor Cell Immunogenicity by Viruses-An Approach to Specific Immunotherapy of Cancer"; <i>Nat Immun. Cell Growth Regul.</i>; Vol. <b>9</b>; pp. 165-172 (1990).</p> <p><b>Shingu, M, et al;</b> "Therapeutic Effects of Bovine Enterovirus Infection on Rabbits with Experimentally Induced Adult T Cell Leukaemia"; <i>Journal of General Virology</i>; Vol. <b>72</b>, pp. 2031-2034 (1991).</p>				

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE  
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-84

10/044,955

APPLICANT

Michael S. Roberts, et al

FILING DATE

TC/A.U.

January 15, 2002

1648

(Use several sheets if necessary)

	Sinkovics, J., et al; "New Developments in the Virus Therapy of Cancer: A Historical Review"; <i>Intervirology</i> ; Vol. 36; pp.193-214 (1993).
	Smith, R.R., et al; "Studies on the Use of Viruses in the Treatment of Carcignoma of the Cervix"; <i>Cancer</i> ; Vol. 9, pp. 1211-1218 (1956).
	Spriggs, D.R., et al; "Attenuated Reovirus Type 3 Strains Generated by Selection of Haemagglutinin Antigenic Variants"; <i>Nature</i> ; Vol. 297; pp. 68-70 (1982).
	Sreevalsan, T.; "Chapter 14 Biologic Therapy with Interferon- $\alpha$ and $\beta$ : Preclinical Studies"; <i>Biologic Therapy of Cancer: Principles and Practice</i> ; pp. 347-364.
	Stojdl et al, Exploiting Tumor-Specific Defects in the Interferon Pathway with a Previously Unknown Oncolytic Virus"; <i>Nature Medicine</i> , Vol. 6, No. 7, pp. 821-825 (2000).
	Stoner, G.D., et al; "Effect of Neuraminidase Pretreatment on the Susceptibility of Normal and Transformed Mammalian Cells to Bovine Enterovirus 261"; <i>Nature</i> ; Vol. 245; pp. 319-320 (1973).
	Strube, M., et al; "Sensitivity of Ortho- and Paramyxovirus Replication to Human Interferon $\alpha$ "; <i>Molec. Biol. Rep.</i> ; Vol. 10, pp. 237-243 (1985).
	Suskind, R.G., et al; "Viral Agents Oncolytic for Human Tumors in Heterologous Host. Oncolytic Effect of Coxsackie B. Viruses"; <i>Oncolytic Effect of Coxsackie Virus</i> ; U.S Dept. of Health, Education & Welfare, N.I.H. Natl Institute of Allergy and Infectious Diseases, and Natl Cancer Inst., Bethesda, MD.; pp. 309-319; (22931) (1956).
	Symons, J.A., et al; "Vaccinia Virus Encodes a Soluble Type I Interferon Receptor of Novel Structure and Broad Species Specificity"; <i>Cell</i> , Vol. 81, pp. 551-560 (1995).
	Tait, D.L., et al; "A Phase I Trial of Retroviral BRCA1sv Gene Therapy in Ovarian Cancer"; <i>Clinical Cancer Research</i> ; Vol. 3; pp. 1959-1968 (1997).
	Takafuji, E.T., et al; "Simultaneous Administration of Live, Enteric-Coated Adenovirus Types 4, 7, and 21 Vaccines: Safety and Immunogenicity"; <i>Journal of Infectious Diseases</i> ; Vol. 140, No. 1; pp. 48-53 (1979).
	Tanaka, N., et al; "Cellular Commitment to Oncogene-Induced Transformation or Apoptosis is Dependent on the Transcription Factor IRF-1"; <i>Cell</i> ; Vol. 77, pp. 829-839 (1994).
	Tanaka, N., et al; "Immunotherapy of a Vaccinia Colon Oncolysate Prepared with Interleukin-2 Gene-Encoded Vaccinia Virus and Interferon- $\alpha$ Increases the Survival of Mice Bearing Syngeneic Colon Adenocarcinoma"; <i>Journal of Immunotherapy</i> ; Vol. 16, No. 4; pp.283-293 (1994).
	Taylor, M.W., et al; "Virus-Induced Regression of Tumor Growth"; <i>Journal of the National Cancer Institute</i> ; Vol. 44, No. 3; pp. 515-519 (1970).
	Verma, I.M., et al; "Gene Therapy – Promises, Problems and Prospects"; <i>Nature</i> ; Vol. 389, pp. 238-242 (1997).
	Wheelock, E.F., et al; "Observations on the Repeated Administration of Viruses to a Patient with Acute Leukemia"; <i>The New England Journal of Medicine</i> ; Vol. 271, No. 13; (1964).
	Xu, B., et al; "Primary Leukemia Cells Resistant to $\alpha$ -Interferon in Vitro are Defective in the Activation of the DNA-Binding Factor Interferon-Stimulated Gene Factor 3"; <i>Blood</i> , Vol. 84, No. 6, pp. 1942-1949 (1994).
	Yu, et al; "Antiviral Action of Interferon- $\beta$ on Newcastle Disease Virus: Selectivity to the Hemagglutinin-Neuraminidase Gene Expression"; <i>Med. Microbiol Immunol</i> ; Vol. 184, pp. 45-52 (1995).
	Zhang, B.; "Process for Preparing Inducing Interferon of Human Body"; <i>Abstract (D4)</i> ; <i>Espacenet Database -12</i> ; Patent No. CN1054192 (1991).
	Zhang, B.; "Attenuated Newcastle Disease Virus for Induction of Interferons to Combat Neoplasm or Viral Diseases"; (1991); Abstract 09; Database CAPLUS, on STN Columbus, OH: Chemical Abstract Service, DN 116: 104333, CN 1054192 A.
	Zhang, J.F., et al; "Treatment of a Human Breast Cancer Xenograft with an Adenovirus Vector Containing an Interferon Gene Results in Rapid Regression Due to Viral Oncolysis and Gene Therapy"; <i>Proc. Natl. Acad. Sci.</i> ; Vol. 93, pp. 4513-4518 (1996).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<b>INFORMATION DISCLOSURE CITATION</b>		ATTY. DOCKET NO.	SERIAL NO.
		2370-84	10/044,955
		APPLICANT	
		Michael S. Roberts, et al	
		FILING DATE	TC/A.U.
		January 15, 2002	1648

*(Use several sheets if necessary)*

*COPY 5 JC6*  
*AUG 09 2004*  
*PATENT & TRADEMARK OFFICE*

	<b>Zhang, J.F., et al;</b> "Gene Therapy with an Adeno-Associated Virus Carrying an Interferon Gene Results in Tumor Growth Suppression and Regression"; <i>Cancer Gene Therapy</i> , Vol. 3, No. 1; pp. 31-38 (1996).
	<b>Zhang, W.W., et al;</b> "High-Efficiency Gene Transfer and High-Level Expression of Wild-Type <i>p53</i> in Human Lung Cancer Cells Mediated by Recombinant Adenovirus"; <i>Cancer Gene Therapy</i> ; Vol. 1, No. 1, pp. 5-13 (1994).
**	<b>Zhenxiang, H., et al;</b> "Studies on Viral Immunotherapy of Ascitic Tumors in Mice – I. Results of Treatment on Viruses of Ehrlich and S180 Ascitic Tumor Cells"; Vol. 6, No. 3; pp. 213-216 (1984).

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Please type a plus sign (+) inside this box



PTO/SB/121 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT &amp; TRADEMARK OFFICE

# CORRESPONDENCE ADDRESS INDICATION FORM

**Address to:**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Direct all correspondence to:

 **Customer Number:** **23117**

 Place Customer  
Number Bar  
Label Here →
**OR**

Type Customer Number here

 Request for Customer Number (PTO/SB/125) submitted herewith.
**in the following listed application(s) or patent(s):**

Patent Number (if appropriate)	Application Number	Patent Date (if appropriate)	U.S. Filing Date
	10/044,955		January 15, 2002

Typed or Printed Name	(Con)	Leonard C. Mitchard	(check one)
Signature		Massey J. W. [Signature] Reg No 32955	<input type="checkbox"/> Applicant or Patentee
Date		August 9, 4002	<input type="checkbox"/> Assignee of record of the entire interest. Statement under 37 C.F.R. § 3.73(b) is enclosed. (Form PTO/SB/96)
Address of signer:	1100 North Glebe Road, 8 <sup>th</sup> Floor Arlington, VA 22202		<input checked="" type="checkbox"/> Attorney or Agent of record  <b>29,009</b> <small>(Reg. No.)</small>

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.\*

 \*Total of 1 forms are submitted.

**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Assistant Commissioner of Patents, Box CN, Washington, DC 20231.